Madrigal Pharmaceuticals, Inc.
MDGLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMadrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company carries a $12.76B market cap, placing it firmly in the large-cap category. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Market Cap
$12.76B
Beta
-1.06
P/E (TTM)
—
P/E (Fwd)
44.71
EPS (TTM)
$-13.67
EPS (Fwd)
$12.38
ROE
-49.4%
ROA
-17.6%
Cash
$812.8M
Total Debt
$347.3M
Free CF
-$156.4M
52W Change
65.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $812.8M in cash comfortably exceeding the $347.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$156.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -49.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
MDGL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MDGL.